BriaCell receives FDA clearance for Bria-OTS IND; reports preclinical data at SITC

BriaCell Therapeutics Corp.

FDA authorized Bria-OTS IND for clinical study of off-the-shelf personalized breast cancer immunotherapy.
Preclinical data at SITC 2023 shows broad immune activation in tumor models by next-gen Bria-OTS+ and Bria-PROS+.
Data indicates personalized HLA-matched platform covers >99% of US population with favorable safety profile.
BriaCell expects to initiate clinical study of Bria-OTS and advance advanced versions for breast and prostate cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.